ABSTRACT

Though the traditional strategies for cancer treatment are still used but they are associated with many drawbacks as developing resistance, toxicities especially at high doses, and lack the financial ability to cover the costs of current chemotherapeutic agents. A number of already exist and approved drugs undergo multiple pre-clinical and clinical studies and were found to have promising anti-tumor action, so they can be repurposed to treat cancer. This strategy are considered cost-saving as compared to discovering and developing a new compound to treat cancer, enable to overcome resistance as they target pathways that differ from those of traditional therapies, and its combination with low dose of the approved anticancer drugs will minimize the adverse effects. Calcium channel blockers are among the drugs that are still being investigated to discover their anti-cancer actions.

KEYWORDS 

calcium channel blockers, cancer, drug repurposing.

REFERENCES

1) Rudrapal M, Khairnar SJ, Jadhav AG. Drug repurposing (DR): an emerging approach in drug. Drug Repurposing: Hypothesis, Molecular Aspects and Therapeutic Applications. 2020 Dec 2;3.
2) Malla R, Viswanathan S, Makena S, Kapoor S, Verma D, Raju AA, Dunna M, Muniraj N. Revitalizing cancer treatment: exploring the role of drug repurposing. Cancers. 2024 Apr 11;16(8):1463.
3) Weth FR, Hoggarth GB, Weth AF, Paterson E, White MP, Tan ST, Peng L, Gray C. Unlocking hidden potential: advancements, approaches, and obstacles in repurposing drugs for cancer therapy. British journal of cancer. 2024 Mar 23;130(5):703-15.4.
4) Aggarwal G, Musyuni P, Mangla B, Goyal RK. Reverse Translational Approach in Repurposing of Drugs for Anticancer Therapy. InDrug Repurposing for Emerging Infectious Diseases and Cancer 2023 Feb 8 (pp. 299-328). Singapore: Springer Nature Singapore.
5) U.S. Food and Drug Administration. FDA-approved prescribing information for arsenic trioxide, celecoxib, mitotane,thalidomide, and tretinoin.
6) Lido P, Romanello D, Tesauro M, Bei A, Perrone MA, Palazzetti D, Noce A, Di Lullo L, Calò L, Cice G. Verapamil: prevention and treatment of cardio-renal syndromes in diabetic hypertensive patients?. European Review for Medical & Pharmacological Sciences. 2022 Mar 1;26(5).
7) Jones KE, Hayden SL, Meyer HR, Sandoz JL, Arata WH, Dufrene K, Ballaera C, Lopez Torres Y, Griffin P, Kaye AM, Shekoohi S. The evolving role of calcium channel blockers in hypertension management: pharmacological and clinical considerations. Current Issues in Molecular Biology. 2024 Jun 22;46(7):6315-27.
8) Dasa O, Smith SM, Pepine CJ. Ischemic Heart Disease. InHypertension 2024 Jan 1 (pp. 363-376). Elsevier.
9) Forman SB, Roy K, Garrett AB. Vasoactive and antiplatelet agents. Comprehensive Dermatologic Drug Therapy E-Book. 2019 Dec 14:358.
10) Zohny YM, Awad SM, Rabie MA, Al-Saidan OA. Synthesis of dihydropyrimidines: isosteres of Nifedipine and evaluation of their calcium channel blocking efficiency. Molecules. 2023 Jan 12;28(2):784.
11) Lee EM. Calcium channel blockers for hypertension: old, but still useful. Cardiovascular Prevention and Pharmacotherapy. 2023 Oct 30;5(4):113-25.
12) Rahman T, Khan MF. Ca+ 2 Channel Blockers. InMedicinal Chemistry for Pharmacy Students 2024 Feb 19 (pp. 40-69). Bentham Science Publishers.
13) El-Mahdy HA, El-Husseiny AA, Kandil YI, El-Din AM. Diltiazem potentiates the cytotoxicity of gemcitabine and 5-fluorouracil in PANC-1 human pancreatic cancer cells through inhibition of P-glycoprotein. Life sciences. 2020 Dec 1;262:118518.
14) Ferreira RJ, Dos Santos DJ, Ferreira MJ. P-glycoprotein and membrane roles in multidrug resistance. Future medicinal chemistry. 2015 Jun 1;7(7):929-46.
15) Patergnani S, Danese A, Bouhamida E, Aguiari G, Previati M, Pinton P, Giorgi C. Various aspects of calcium signaling in the regulation of apoptosis, autophagy, cell proliferation, and cancer. International journal of molecular sciences. 2020 Nov 6;21(21):8323.
16) Varghese E, Samuel SM, Sadiq Z, Kubatka P, Liskova A, Benacka J, Pazinka P, Kruzliak P, Büsselberg D. Anti-cancer agents in proliferation and cell death: the calcium connection. International journal of molecular sciences. 2019 Jun 20;20(12):3017.
17) Li YH, Zheng CR, Liu Y, Wang K, Zhou FF, Dong X, Yuan T, He QJ, Zhu H, Yang B. The role of calcium signaling in organotropic metastasis of cancer. Acta Pharmacologica Sinica. 2025 Jul;46(7):1801-12.
18) Liu X, Feng C, Yan L, Cao J, Zhu X, Li M, Zhao G. Calcium channels as pharmacological targets for cancer therapy. Clin Exp Med. 2025;25(1):94. doi:10.1007/s10238-025-01632-z.
19) Wong BS, Chiu LY, Tu DG, Sheu GT, Chan TT. Anticancer Effects of Antihypertensive L-Type Calcium Channel Blockers on Chemoresistant Lung Cancer Cells via Autophagy and Apoptosis. Cancer Manag Res. 2020 Mar 13;12:1913-1927.
20) Panneerpandian P, Rao DB, Ganesan K. Calcium channel blockers lercanidipine and amlodipine inhibit YY1/ERK/TGF-β mediated transcription and sensitize the gastric cancer cells to doxorubicin. Toxicology in Vitro. 2021 Aug 1;74:105152.
21) Alqudah MAY, Al-Samman R, Azaizeh M, Alzoubi KH. Amlodipine inhibits proliferation, invasion, and colony formation of breast cancer cells. Biomed Rep. 2022;16(6):50.
22) Fu B, Dou X, Zou M, Lu H, Wang K, Liu Q, Liu Y, Wang W, Jin M, Kong D. Anticancer effects of amlodipine alone or in combination with gefitinib in non-small cell lung cancer. Front Pharmacol. 2022;13:902305.
23) Chen YM, Yang WQ, Gu CW, Fan YY, Liu YZ, Zhao BS. Amlodipine inhibits the proliferation and migration of esophageal carcinoma cells through the induction of endoplasmic reticulum stress. World J Gastroenterol. 2024;30(4):367-380.
24) Mondal SK, Hong CS, Han J, Diergaarde B, Zandberg DP, Whiteside TL. Amlodipine, an L-type Ca²⁺ channel inhibitor, regulates release of extracellular vesicles from tumor cells. Carcinogenesis. 2025;46(2):bgaf016.
25) Principe DR, Aissa AF, Kumar S, Pham TND, Underwood PW, Nair R, et al. Calcium channel blockers potentiate gemcitabine chemotherapy in pancreatic cancer. Proc Natl Acad Sci U S A. 2022;119(18):e2200143119.
26) Panneerpandian P, Rao DB, Ganesan K. Calcium channel blockers lercanidipine and amlodipine inhibit YY1/ERK/TGF-β mediated transcription and sensitize the gastric cancer cells to doxorubicin. Toxicol In Vitro. 2021;74:105152.
27) Liu X, Shen B, Zhou J, Hao J, Wang J. The L-type calcium channel CaV1.3: A potential target for cancer therapy. J Cell Mol Med. 2024;28(19):e70123.
28) Lin JL, Wang X, Ma S, Yang D, Li K, Li D, et al. Calcium channels as therapeutic targets in head and neck squamous cell carcinoma: current evidence and clinical trials. Front Oncol. 2024;14:1516357.

Cite this article

Obayes, S. K., Wannas, A. N., AL-Shaibani, A. J. N., & Ghaleb, R. A. (2026). Repurposing of L-Type Calcium Channel Blockers for Cancer Treatment. INTERNATIONAL JOURNAL OF HEALTH & MEDICAL RESEARCH, 5(7), 640-643. https://doi.org/10.58806/ijhmr.2026.v5i7n10